Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.49 |
| ▸ | TERT | O14746 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2496039 | 0.88 | — | — | |
| SCHEMBL593619 | 0.81 | TERT (0.42) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL27831718 | 0.81 | TERT (0.42) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL593822 | 0.81 | TERT (0.42) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL31366376 | 0.81 | TBXAS1 (0.46) | TBXAS1TERTALOX15TAAR1HTR1A | |
| SCHEMBL9777191 | 0.81 | TBXAS1 (0.60) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL3431746 | 0.81 | TBXAS1 (0.66) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL7287192 | 0.81 | TBXAS1 (0.49) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL503743 | 0.79 | TBXAS1 (0.69) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL28062565 | 0.79 | TBXAS1 (0.69) | TBXAS1TERTALOX15TAAR1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2909189-A1 | HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt | Janssen Pharmaceutica, N.V. (BE) | 2015-08-26 | — | — | EP | claimed |
| EP-2909193-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | Janssen Pharmaceutica N.V. (BE) | 2015-08-26 | — | — | EP | claimed |
| EP-2909192-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | Janssen Pharmaceutica, N.V. (BE) | 2015-08-26 | — | — | EP | claimed |
| WO-2014062658-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-24 | — | — | WO | claimed |
| WO-2014062667-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-24 | — | — | WO | claimed |
| WO-2014062655-A1 | HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-24 | — | — | WO | claimed |
| WO-2023102140-A1 | TMPRSS2 INHIBITORS AND METHODS OF USE | TOPSPIN THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20180092915-A1 | SODIUM CHANNEL BLOCKERS FOR SKIN DISORDERS | PARION SCIENCES, INC. (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180092915-A1 | SODIUM CHANNEL BLOCKERS FOR SKIN DISORDERS | PARION SCIENCES, INC. (US) | 2018-04-05 | — | — | US | disclosed |
| US-9849129-B2 | Sodium channel blockers for skin disorders | PARION SCIENCES, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9849129-B2 | Sodium channel blockers for skin disorders | PARION SCIENCES, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| CN-105209453-B | The quinolyl conditioning agent of the methylene connection of ROR γ T | 詹森药业有限公司 | 2017-06-20 | — | — | CN | disclosed |
| US-20170020870-A1 | SODIUM CHANNEL BLOCKERS FOR SKIN DISORDERS | PARION SCIENCES, INC. | 2017-01-26 | — | — | US | disclosed |
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2320907-A1 | THERAPEUTIC COMPOUNDS | Merck & Co., Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010017047-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20080200476-A1 | ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200476-A1 | ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092915-A1 | SODIUM CHANNEL BLOCKERS FOR SKIN DISORDERS | SCNN1B, SCNN1A, SCNN1G | TBXAS1 1556/4885TERT 3687/4885ALOX15 2921/4885 |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | TBXAS1 1642/4885TERT 1561/4885ALOX15 863/4885 |
| US-20110207711-A1 | Therapeutic Compounds | WEE2, MARK3, WEE1 | TBXAS1 3652/4885TERT 2734/4885ALOX15 4850/4885 |
| US-20170020870-A1 | SODIUM CHANNEL BLOCKERS FOR SKIN DISORDERS | SCNN1B, SCNN1A, SCNN1G | TBXAS1 1556/4885TERT 3687/4885ALOX15 2921/4885 |
| US-20080200476-A1 | ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | KCNH1, CACNA1B, CACNA1C | TBXAS1 1699/4885TERT 4172/4885ALOX15 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.